MK-0952, also known as verinurad, is a selective inhibitor of the urate transporter 1 (URAT1), a protein responsible for uric acid reabsorption in the proximal tubules of the kidney. It is primarily investigated for the treatment of hyperuricemia, a key factor in gout and related conditions. By blocking URAT1, MK-0952 increases uric acid excretion in the urine, thereby reducing serum uric acid levels and preventing gout flares. Research has focused on its use as an adjunct therapy with xanthine oxidase inhibitors like allopurinol or febuxostat, particularly in patients with inadequate response to standard treatments. Clinical trials have demonstrated its efficacy in lowering uric acid levels and improving gout management, with ongoing studies evaluating long-term safety, including renal effects, in diverse populations.